Petros Pharmaceuticals, Inc.
PTPI OTC
SEC CIK 1815903
Follow Petros Pharmaceuticals
Weekly email: filings, results, news
Net income
−$955.6K
−117.6% vs same quarter last year
EPS, diluted
−$0.30
+75% vs same quarter last year
Operating cash flow
−$863.9K
+71.3% vs same quarter last year
Operating income
−$988.5K
+45.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | $1.9M |
| FY24 | $5.1M | −$14.3M |
| FY23 | $5.8M | −$8.2M |
| FY22 | $6M | −$20M |
| FY21 | $7.8M | −$9M |
| FY20 | $9.6M | −$20.6M |
| FY19 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | - | - |
| FY24 | 76.3% | −90.5% | −280.1% |
| FY23 | 72% | −233.9% | −140.2% |
| FY22 | 61.8% | −332.4% | −334.4% |
| FY21 | 79.5% | −231.1% | −115% |
| FY20 | 57.7% | −180.8% | −215.3% |
| FY19 | - | - | - |
- Petros Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Petros Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | - | −66.4% |
| FY24 | −280.1% | −87% |
| FY23 | −140.2% | −128.5% |
| FY22 | −334.4% | −143.6% |
| FY21 | −115% | −137.7% |
| FY20 | −215.3% | −134.3% |
| FY19 | - | −125.9% |
News
No stories filed under Petros Pharmaceuticals yet - coverage appears here as the news feed clusters it.